Home » Clinical Trials »  Search Clinical Trials

Therapeutic Areas:  |  Hematology  |  Musculoskeletal  |  Oncology

Search Medical Condition
Please enter condition
Please choose location

Acute Myeloid Leukemia Clinical Trials

A listing of Acute Myeloid Leukemia medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

RESULTS

Found (185) clinical trials

This randomized phase III trial studies how well bortezomib and sorafenib tosylate work in treating patients with newly diagnosed acute myeloid leukemia. Bortezomib and sorafenib tosylate may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy work in different ...

Phase

People with acute myeloid leukemia are asked to participate in a research study being conducted by Montefiore Medical Center.

Phase N/A

For more information please visit: http://clinicaltrials.gov/ct2/show/NCT01307579?term=Children%27s+Oncology+Group&cond=Prevent+Invasive+Fungal+Infection+in+Children+Undergoing+Chemotherapy+for+Acute+Myeloid+Leukemia+%28AML%29&rank=1

Phase N/A

Phase I/II Study of Selective Inhibitor of Nuclear Export (SINE) Selinexor (KPT-330) + Sorafenib in Acute Myeloid Leukemia

Study Groups If you are found to be eligible to take part in this study, you will be assigned to a study group based on when you join this study. Up to 3 groups of up to 6 participants will be enrolled in Part 1 of the study, and up ...

Phase

Alisertib in Treating Patients With Myelofibrosis or Relapsed or Refractory Acute Megakaryoblastic Leukemia

PRIMARY OBJECTIVES: I. Determine the safety profile of alisertib in patients with acute megakaryoblastic leukemia (AMKL) and in patients with myelofibrosis (MF). SECONDARY OBJECTIVES: I. Determine preliminary efficacy of alisertib in both populations. TERCIARY OBJECTIVES: I. Describe pharmacodynamics (PD) effects of alisertib in peripheral blood and/or bone marrow samples. II. ...

Phase N/A

Nivolumab in Acute Myeloid Leukemia (AML) in Remission at High Risk for Relapse

Study Drug Administration: Each study cycle is 28 days. If you are found to be eligible to take part in this study, you will receive nivolumab by vein over about 1 hour on Days 1 and 15 of each cycle. After Cycle 6, you may receive nivolumab 1 time each ...

Phase

A Study of Lenalidomide in Pediatric Subjects With Relapsed or Refractory Acute Myeloid Leukemia

This is a multicenter, open-label, single-arm, Phase 2, Simon's Optimal two-stage design study, with an Optional Extension Phase (OEP), that will assess the activity, safety and Pharmacokinetics (PK) of lenalidomide in pediatric subjects from 1 to ≤ 18 years of age with second or greater Relapsed or Refractory Acute Myeloid ...

Phase